Premium
Clinical trial participation among patients enrolled in the Glioma Outcomes Project
Author(s) -
Chang Susan M.,
Barker Fred G.,
Schmidt Meic H.,
Sloan Andrew E.,
Kasper Rachel,
Phillips Leslie,
Shih Karen,
Hariharan Subramanian,
Berger Mitchel S.
Publication year - 2002
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.10536
Subject(s) - medicine , glioma , clinical trial , multivariate analysis , logistic regression , performance status , univariate analysis , observational study , prospective cohort study , physical therapy , surgery , cancer , cancer research
BACKGROUND Patient participation in well‐designed and conducted clinical trials enables researchers to test new therapies. An understanding of the variables that possibly influence patient enrollment may help in patient recruitment for future trials. The authors evaluated factors that influenced patient enrollment in clinical trials using a prospective, large, multi‐institutional registry of patients with malignant glioma. METHODS Data were examined from 708 patients who underwent first or second surgery for a malignant glioma who were enrolled in the Glioma Outcomes Project, which is a prospective observational data base that captures clinical practice patterns. The frequency of clinical trial participation and the variables that may have been associated with trial participation were evaluated. These variables included age, gender, race, household income, educational level, first versus second craniotomy, histology, and whether the patient was treated at an academic institution. RESULTS One hundred fifty‐one of 708 patients (21.3%) participated in a clinical trial, which was higher than the participation reported typically for patients with other types of primary malignancies. In univariate analysis, race, histology, and first craniotomy were significant between the two groups, with Caucasian patients and patients with glioblastoma histology showing higher participation rates. In a multivariate logistic regression model, significant predictors included young age and glioblastoma multiforme histology. CONCLUSIONS The authors present information on factors that may influence clinical trial participation among patients with malignant glioma and compare their data with information described previously on patients with other types of malignant disease. The percent of participation among the patients in the current study was greater than among patients with other primary tumor sites. Strategies should be implemented to improve recruitment to neuro‐oncology trials, especially in elderly and minority populations. Cancer 2002;94:2681–7. © 2002 American Cancer Society. DOI 10.1002/cncr.10536